AequoScreen® calcium assays deliver
AlphaSrceen® SureFire® Phospho-ERK 1/2 assay
AequoScreen calcium mobilization assays deliver superior performance for use in HTS, finds GSK.
As seen in Cell-based Assay News, a study conducted by Parita Shah, team leader for screening and compound profiling at GlaxoSmithKline (GSK), compared PerkinElmer’s AequoScreen (Aequorin) assays on the LumiLux cellular screening platform to Molecular Devices’ FLIPR® dye technology. The data clearly demonstrates that AequoScreen and LumiLux have far superior performance to FLIPR. Dr. Shah and her team ran two HTS campaigns in parallel and found that the luminescent AequoScreen assay required two fewer employees, had a five-plate-per-hour higher throughput and confirmed 55 percent more single-shot actives at CX50.
The combination of PerkinElmer’s AequoScreen assays on the LumiLux cellular screening platform had numerous advantages over FLIPR.
- Robust data: reduced variability, less rejected curves, fewer false positives due to auto-fluorescence
- Higher throughput: 5 plates/hour higher when comparing 2 FLIPRs with a robot to 1 stand-alone LumiLux
- Fewer man hours: only 1 person was required to run the LumiLux compared to 3 FTEs for the 2 FLIPRs
Click here to see a demo of the LumiLux on PE TV.
Click here to download pdf of the complete article.
1LoBuono C. Glaxo shows Aequorin superior to FLIPR; shifts to luminescence for HTP imaging. Cell-based Assay News Oct. 19, 2007;4(40).
©2007-2008 PerkinElmer. All rights reserved.
PerkinElmer,
AequoScreen and LumiLux are registered trademarks of PerkinElmer, Inc.
FLIPR is a registered trademark of MDS Analytical Technologies.